Back to results
US 10,881,674 B2Granted
Synthetic composition for treating metabolic disorders
AssigneeGlycom A/S
InventorsBruce McConnell, Louise Kristine Vigsnæs, Emma Elison
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).
Claims12
A method comprising:
- administering to a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes, a product consisting of an effective amount of one or more neutral human milk oligosaccharides (HMOs) comprising at least one fucosylated HMO selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), and difucosyllactose (DFL), and at least one non-fucosylated HMO selected from lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT), wherein the one or more neutral HMOs are administered in an amount effective to:
- increase a relative abundance of Bifidobacterium adolescentis in the non-infant patient;
- and
- improve in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation.
1 more element
A method comprising:
- administering to a non-infant patient having an obesity-related metabolic disorder an effective amount of one to five neutral human milk oligosaccharides (HMOs) comprising at least one fucosylated HMO selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), and difucosyllactose (DFL), and at least one non-fucosylated HMO selected from lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) wherein the one to five neutral HMOs are administered in an amount effective to:
- increase a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant patient;
- and
- improve in the non-infant patient at least one condition selected from reduced metabolic endotoxemia, an improved level of a glucagon-like peptide, and reduction in an inflammatory marker associated with the metabolic disorder.
1 more element
A method comprising:
- administering to a non-infant patient having an obesity-related metabolic disorder a synthetic composition consisting of an effective amount of one or more neutral HMOs selected from 2′-FL, 3′-FL, DFL, LNT, and LNnT, and optionally one or more excipients, wherein the one or more neutral HMOs are administered in an amount effective to:
- increase a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant patient;
- and
- improve in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, and improved gut barrier function.
1 more element
Dependencies are inferred from the claim text.